Composition and method for fertility therapy using nutritional supplements
Inventors
Andrews, Kelly • Grunebaum, Amos N.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8974838-B2
Publication Date
2015-03-10
Expiration Date
Abstract
A new composition and method are described for male fertility therapy. In one particular embodiment, the composition comprises Lepidium meyenii, carnitine and Coenzyme Q10. When it is administered to males as fertility therapy following the recommended therapeutic regimen, enhanced sperm count, sperm quality, and sperm motility results.
Core Innovation
The document describes a human male fertility therapy that uses a combined nutritional supplement composition intended to enhance human male fertility. The composition includes a sperm count enhancing dose of Lepidium meyenii, a sperm quality enhancing dose of carnitine, a sperm motility enhancing dose of Coenzyme Q10, together with ginseng.
The problem being solved is human male fertility, including oligoasthenospermic men, where male fertility is associated with sperm count, sperm motility, and sperm quality deficiencies. The background and examples frame the need for a fertility-enhancing approach that targets multiple sperm parameters rather than a single factor.
The composition is further described as including ingredient options such as Lepidium meyenii, including an extract of Lepidium hypocotyl, carnitine, and Coenzyme Q10, with ginseng specified as Panax ginseng. Additional supplemental components are described as optional, including grape seed, with proanthocyanidins, and an optional broad vitamins and minerals blend. A clinical example is presented in which an active group receives the composition versus placebo, and the outcomes include increased pregnancy rate and improved semen parameters.
Claims Coverage
The provided material includes two independent claims directed to a fertility-enhancing composition for human male fertility therapy. Across the independent claims, the coverage centers on four named components and their roles: Lepidium meyenii or an extract of Lepidium hypocotyl for sperm count, carnitine for sperm quality, Coenzyme Q10 for sperm motility, and ginseng.
Fertility-enhancing composition with Lepidium meyenii, carnitine, Coenzyme Q10, and ginseng
A fertility-enhancing composition for human male fertility therapy comprising a sperm count enhancing dose of Lepidium meyenii, a sperm quality enhancing dose of carnitine, a sperm motility enhancing dose of Coenzyme Q10, and ginseng.
Fertility-enhancing composition with Lepidium hypocotyl extract, carnitine, Coenzyme Q10, and ginseng
A fertility-enhancing composition for human male fertility therapy comprising a sperm count enhancing dose of an extract of Lepidium hypocotyl, a sperm quality enhancing dose of carnitine, a sperm motility enhancing dose of Coenzyme Q10, and ginseng.
The independent claims cover a combined fertility-enhancing composition for human male fertility therapy that assigns Lepidium meyenii or an extract of Lepidium hypocotyl to sperm count enhancement, carnitine to sperm quality enhancement, Coenzyme Q10 to sperm motility enhancement, and ginseng as a further component.
Stated Advantages
Increased pregnancy rate in an active group compared to placebo in a clinical example.
Improved semen parameters in the active group, including vitality, morphology, forward motile sperm, and total motile sperm.
Enhancement of sperm count, sperm quality, and sperm motility as intended effects of the composition components.
Documented Applications
Human male fertility therapy in oligoasthenospermic men, evaluated in a placebo-controlled example with increased pregnancy rate and improved semen parameters in the active group.
Interested in licensing this patent?